ES2642624T3 - Polipéptidos de leptina canina modificados - Google Patents

Polipéptidos de leptina canina modificados Download PDF

Info

Publication number
ES2642624T3
ES2642624T3 ES14722420.8T ES14722420T ES2642624T3 ES 2642624 T3 ES2642624 T3 ES 2642624T3 ES 14722420 T ES14722420 T ES 14722420T ES 2642624 T3 ES2642624 T3 ES 2642624T3
Authority
ES
Spain
Prior art keywords
leptin polypeptides
modified canine
canine leptin
modified
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14722420.8T
Other languages
English (en)
Inventor
Michael BLEDSOE
Peter Connor Canning
Michael Deguzman
Nick Knudsen
Ianina VALENTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Ambrx Inc
Original Assignee
Eli Lilly and Co
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co, Ambrx Inc filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2642624T3 publication Critical patent/ES2642624T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES14722420.8T 2013-03-13 2014-03-12 Polipéptidos de leptina canina modificados Active ES2642624T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779337P 2013-03-13 2013-03-13
US201361779337P 2013-03-13
PCT/US2014/024706 WO2014165189A2 (en) 2013-03-13 2014-03-12 Modified canine leptin polypeptides

Publications (1)

Publication Number Publication Date
ES2642624T3 true ES2642624T3 (es) 2017-11-17

Family

ID=50680127

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14722420.8T Active ES2642624T3 (es) 2013-03-13 2014-03-12 Polipéptidos de leptina canina modificados

Country Status (16)

Country Link
US (1) US10105447B2 (es)
EP (1) EP2970424B1 (es)
JP (2) JP6423852B2 (es)
KR (1) KR20150126035A (es)
CN (1) CN105121461A (es)
AU (1) AU2014248617B2 (es)
BR (1) BR112015021364A2 (es)
CA (1) CA2901928C (es)
DK (1) DK2970424T3 (es)
ES (1) ES2642624T3 (es)
HU (1) HUE033443T2 (es)
IL (1) IL240964B (es)
MX (1) MX2015012631A (es)
PL (1) PL2970424T3 (es)
PT (1) PT2970424T (es)
WO (1) WO2014165189A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220016211A1 (en) * 2020-01-08 2022-01-20 Bristol-Myers Squibb Company Fgf-21 conjugate formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2247503A1 (en) * 1996-03-01 1997-09-04 Amgen Inc. Canine ob protein compositions and methods
JP2000279171A (ja) 1999-03-30 2000-10-10 Morinaga & Co Ltd イヌ肥満遺伝子、その遺伝子産物とその製造法及び測定試薬と測定法
AU782230B2 (en) * 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
CA2502029C (en) 2002-10-16 2014-06-10 The Scripps Research Institute Site specific incorporation of keto amino acids into proteins
CN101113175A (zh) * 2007-04-28 2008-01-30 中国科学院西北高原生物研究所 鼠兔家族瘦素蛋白及其cDNA序列
NZ602170A (en) * 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
JP5413766B2 (ja) * 2008-03-10 2014-02-12 株式会社シバヤギ レプチン測定方法
SG178119A1 (en) * 2009-07-31 2012-03-29 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof

Also Published As

Publication number Publication date
DK2970424T3 (en) 2017-07-31
CN105121461A (zh) 2015-12-02
CA2901928C (en) 2017-10-10
KR20150126035A (ko) 2015-11-10
HUE033443T2 (en) 2017-11-28
CA2901928A1 (en) 2014-10-09
AU2014248617A1 (en) 2015-09-17
WO2014165189A2 (en) 2014-10-09
IL240964A0 (en) 2015-11-30
IL240964B (en) 2019-07-31
AU2014248617B2 (en) 2016-05-19
EP2970424B1 (en) 2017-06-21
WO2014165189A3 (en) 2014-11-27
JP2017110024A (ja) 2017-06-22
PT2970424T (pt) 2017-08-25
EP2970424A2 (en) 2016-01-20
JP2016514144A (ja) 2016-05-19
US20150366983A1 (en) 2015-12-24
JP6434071B2 (ja) 2018-12-05
PL2970424T3 (pl) 2017-11-30
MX2015012631A (es) 2016-06-21
US10105447B2 (en) 2018-10-23
JP6423852B2 (ja) 2018-11-14
BR112015021364A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
ES2642354T3 (es) Bastidor de retención para módulos de conectores de enchufe
ES2644844T3 (es) Mecanismo de soporte
ES2643578T3 (es) Pieza embellecedora acústica ligera
DK3004838T3 (da) Billeddannende cytometer
DK3401372T3 (da) Blæk til laserbilleddannelse
ES2642212T3 (es) Cierre de cremallera
ES2643814T3 (es) Carretilla elevadora equipada con medios de estabilización
ITUD20130161A1 (it) "apparato rotante monopiede"
ES2642415T3 (es) Amortiguador de carretera
FR3000606B1 (fr) Capteur d'image
DOS2014000063S (es) Golosinas para mascotas
JP2016505534A5 (es)
FR3010837B1 (fr) Capteur d'image terahertz
ES2641554T3 (es) Kit de piezas para colocación de anclaje quirúrgico
JP2014148606A5 (es)
ES2642175T3 (es) Cable
ES2644995T3 (es) Módulo de filtro
ES2642624T3 (es) Polipéptidos de leptina canina modificados
ES2644989T3 (es) Mecanismo de activación para encendedor
JP2014205658A5 (es)
ES2644293T3 (es) Dispositivo de compresión médico
ES2642712T3 (es) Péptidos de foenixina
ES2644814T3 (es) Montaje de rodillo de alimentación
ES2643581T3 (es) Sistema de reproducción de imágenes estereoscópicas por proyección
ES2643596T3 (es) Dispositivo de cierre con un cilindro de cierre